GU Cancers Symposium 2013 - Sipuleucel-T delayed time to first use of opioid analgesics in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in the IMPACT trial, by Eric J. Small, MD, et al. - Poster

ORLANDO, FL, USA (UroToday.com) - Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response against prostate cancer. Sipuleucel-T has been demonstrated to improve overallsurvival in three Phase III trials (including the pivotal IMPACT study) in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)....Click here to enlarge and view the poster.

IMPACT TFOA Sip-T small thumb
                                (Click thumbnail to enlarge poster)

 

Presented by Eric J. Small,1 Celestia S Higano,2 Philip W Kantoff,3 James B Whitmore,4 Mark W Frohlich,4 and Daniel P Petrylak5 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

1Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA; 2Departments of Oncology and Urology, School of Medicine, University of Washington, Seattle, WA, USA; 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 4Dendreon Corporation, Seattle, WA, USA; 5Department of Medical Oncology, Smilow Cancer Hospital at Yale, New Haven, CT, USA



gucancerssympalt



View Full 2013 GU Cancers Symposium Coverage